Skip to main content
Premium Trial:

Request an Annual Quote

Cellectricon, AstraZeneca Extend Collaboration

NEW YORK (GenomeWeb News) – Cellectricon today said that it has signed a new agreement with AstraZeneca, under which the drug giant will use two of the firm’s DynaFlow HT platforms for ion channel screening.
The partners initially started collaborating in 2006 on developing an ion channel screening platform. The results of the collaboration demonstrated the performance capabilities of the cell-based microfluidic screening platform, said Gothenburg, Sweden-based Cellectricon.
The company said that the DynaFlow HT System will be commercially launched in 2009.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.